News and Media
News Updates
Intelligent Bio Solutions Reaches Key Milestone in Biosensor Platform Development
Intelligent Bio Solutions Reaches Key Milestone in Biosensor Platform Development NEW YORK, January 23, 2023 (GLOBE NEWSWIRE) – Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or
Intelligent Bio Solutions Inc. Announces Closing of Private Placement Offering
Intelligent Bio Solutions Inc. Announces Closing of Private Placement Offering NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a
Intelligent Bio Solutions Inc. Announces Cancellation of FY 2021 Annual Meeting of Stockholders
Intelligent Bio Solutions Inc. Announces Cancellation of FY 2021 Annual Meeting of Stockholders Company Intends to Hold FY 2022 Annual Meeting in February 2023. NEW
Intelligent Bio Solutions Inc. Reports First Quarter Ending September 30, 2022, Preliminary Financial Results and Recent Business Highlights
Intelligent Bio Solutions Inc. Reports First Quarter Ending September 30, 2022, Preliminary Financial Results and Recent Business Highlights Acquired Intelligent Fingerprinting Limited and its proprietary
Intelligent Bio Solutions Inc. Announces Airline Adopts Fingerprint Drug Screening System for In-house Testing
Intelligent Bio Solutions Inc. Announces Airline Adopts Fingerprint Drug Screening System for In-house Testing Eastern Airways to use portable, hygienic, non-invasive fingerprint sweat test
Intelligent Bio Solutions Inc. Announces Leading U.K. Container Haulier Switching to Fingerprint Drug Screening System for In-house Testing
Intelligent Bio Solutions Inc. Announces Leading U.K. Container Haulier Switching to Fingerprint Drug Screening System for In-house Testing Goldstar Transport to Remove Urine Testing
GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology
GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (INBS) and Announces Key Executive Appointments Name change to more closely reflect firm’s
GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology
GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology The transaction further solidifies GBS’ leadership in non-invasive, real-time diagnostic testing
GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood
GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood The trial is single center, prospective study collecting coincident samples
GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus
GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus New York, NY, June 23, 2022 (GLOBE NEWSWIRE) – GBS Inc. (Nasdaq: GBS),
GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse
GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse Intelligent
GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights
GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights Initiated prospective study to collect coincident samples of oral fluid and blood following
GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center
GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center The trial is single center, prospective study to
GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study
GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study New York, NY, November 30, 2021 – GBS Inc. (Nasdaq: GBS), a life
GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights Clinical Validation Study Results for SARS CoV2 Ab Test.Evaluating site locations for build
GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights
GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights Awarded $4.7 Million Government Grant Funding to support the
GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test
GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test New York, NY, July 26, 2021
GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology New York, NY, July 8, 2021 – GBS (Nasdaq: GBS), a life
Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey
Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey Global results show 90% of patients are in favor of a
GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights
GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half
GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test
GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test NEW YORK APRIL 15, 2021 — GBS, Inc. (GBS), a life
GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests
GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests New York, NY, February
Harvard’s Wyss Institute collaborates with GBS Inc. on the Wyss’ eRapid-based COVID-19 diagnostic to help curb the pandemic
Harvard’s Wyss Institute collaborates with GBS Inc. on the Wyss’ eRapid-based COVID-19 diagnostic to help curb the pandemic Combination of the Wyss’ electrochemical sensing technology
FDA Engagement Commences for Saliva Glucose Biosensor in the US
FDA Engagement Commences for Saliva Glucose Biosensor in the US SYDNEY – May 6, 2020 The iQ Group Global is pleased to announce that Life
The iQ Group Global Partners with Harvard University for Real-Time, Printable COVID-19 Diagnostic Test
The iQ Group Global Partners with Harvard University for Real-Time, Printable COVID-19 Diagnostic Test SYDNEY – May 29, 2020 The iQ Group Global has announced
The iQ Group Global Introduces the Saliva Glucose Biosensor
The iQ Group Global Introduces the Saliva Glucose Biosensor The world’s first non-invasive, saliva-based glucose test for diabetes management SYDNEY – February , 2019 –
Media
